Literature DB >> 35505765

Insights on the Risk of Hepatocellular Carcinoma in PatientsWith Nonalcoholic Steatohepatitis.

Amit Singal1, Willis C1.   

Abstract

Entities:  

Year:  2022        PMID： 35505765      PMCID： PMC9053500     

Source DB:  PubMed          Journal:  Gastroenterol Hepatol (N Y)        ISSN： 1554-7914


× No keyword cloud information.
  8 in total

Review 1.  AGA Clinical Practice Update on Screening and Surveillance for Hepatocellular Carcinoma in Patients With Nonalcoholic Fatty Liver Disease: Expert Review.

Authors:  Rohit Loomba; Joseph K Lim; Heather Patton; Hashem B El-Serag
Journal:  Gastroenterology       Date:  2020-01-30       Impact factor: 22.682

2.  Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases.

Authors:  Jorge A Marrero; Laura M Kulik; Claude B Sirlin; Andrew X Zhu; Richard S Finn; Michael M Abecassis; Lewis R Roberts; Julie K Heimbach
Journal:  Hepatology       Date:  2018-08       Impact factor: 17.425

3.  Models estimating risk of hepatocellular carcinoma in patients with alcohol or NAFLD-related cirrhosis for risk stratification.

Authors:  George N Ioannou; Pamela Green; Kathleen F Kerr; Kristin Berry
Journal:  J Hepatol       Date:  2019-05-28       Impact factor: 25.083

Review 4.  Incidence of Hepatocellular Carcinoma in Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review, Meta-analysis, and Meta-regression.

Authors:  Lorenzo A Orci; Marco Sanduzzi-Zamparelli; Berta Caballol; Victor Sapena; Nicola Colucci; Ferran Torres; Jordi Bruix; María Reig; Christian Toso
Journal:  Clin Gastroenterol Hepatol       Date:  2021-05-28       Impact factor: 11.382

Review 5.  Rational HCC screening approaches for patients with NAFLD.

Authors:  Amit G Singal; Hashem B El-Serag
Journal:  J Hepatol       Date:  2021-09-09       Impact factor: 25.083

Review 6.  Prevention of NAFLD-associated HCC: Role of lifestyle and chemoprevention.

Authors:  Naomi F Lange; Pompilia Radu; Jean-François Dufour
Journal:  J Hepatol       Date:  2021-07-31       Impact factor: 25.083

7.  A blood-based prognostic liver secretome signature and long-term hepatocellular carcinoma risk in advanced liver fibrosis.

Authors:  Naoto Fujiwara; Masahiro Kobayashi; Austin J Fobar; Ayaka Hoshida; Cesia A Marquez; Bhuvaneswari Koneru; Gayatri Panda; Masataka Taguri; Tongqi Qian; Indu Raman; Quan-Zhen Li; Hiroki Hoshida; Hitomi Sezaki; Hiromitsu Kumada; Ryosuke Tateishi; Takeshi Yokoo; Adam C Yopp; Raymond T Chung; Bryan C Fuchs; Thomas F Baumert; Jorge A Marrero; Neehar D Parikh; Shijia Zhu; Amit G Singal; Yujin Hoshida
Journal:  Med (N Y)       Date:  2021-04-21

Review 8.  Surveillance for Hepatocellular Carcinoma in Patients with NASH.

Authors:  Philippe Kolly; Jean-François Dufour
Journal:  Diagnostics (Basel)       Date:  2016-06-07
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.